About this trial
Primary aldosteronism (PA) is the most common cause of secondary hypertension. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is more accurate than the traditional radioimmunoassay method in measuring aldosterone. This study aims to establish a more precise diagnostic cutoff value for the captopril stimulation test (CCT) by measuring aldosterone levels using LC-MS/MS. The investigators will combine the detection results of CCT from healthy volunteers and suspected PA patients, etc., to determine the new CCT cutoff value. The investigators expect to improve the diagnostic accuracy of PA, helping clinicians identify this curable cause of hypertension earlier and more accurately, and achieving precise treatment.
Eligibility criteria
Qualifiers
Age 18-70 years old
BMI: 18.5-23.9kg/m²
Gender not restricted
Blood pressure: 100-120/60-80mmHg
Disqualifiers
Those with a family history of hypertension or with clinical manifestations of secondary hypertension
Those who have been taking drugs that may affect the RAAS system for a long time (such as contraceptives, steroids, etc.)
Those with cardiac dysfunction or severe arrhythmia and unable to tolerate the test
Patients with suspected primary aldosteronism in the outpatient setting
Trial design
Treatments tested in this trial
- Captopril inhibition test(CCT)